Article | Open

Evidence for ACTN3 as a genetic modifier of Duchenne muscular dystrophy

Published online:


Duchenne muscular dystrophy (DMD) is characterized by muscle degeneration and progressive weakness. There is considerable inter-patient variability in disease onset and progression, which can confound the results of clinical trials. Here we show that a common null polymorphism (R577X) in ACTN3 results in significantly reduced muscle strength and a longer 10 m walk test time in young, ambulant patients with DMD; both of which are primary outcome measures in clinical trials. We have developed a double knockout mouse model, which also shows reduced muscle strength, but is protected from stretch-induced eccentric damage with age. This suggests that α-actinin-3 deficiency reduces muscle performance at baseline, but ameliorates the progression of dystrophic pathology. Mechanistically, we show that α-actinin-3 deficiency triggers an increase in oxidative muscle metabolism through activation of calcineurin, which likely confers the protective effect. Our studies suggest that ACTN3 R577X genotype is a modifier of clinical phenotype in DMD patients.


Duchenne muscular dystrophy (DMD) is an X-linked genetic disorder characterized by progressive muscle degeneration and weakness. DMD is caused by mutations in the DMD gene, resulting in loss of dystrophin protein at the muscle membrane1. To date, the only proven palliative therapy for DMD is chronic corticosteroid (that is, prednisone or deflazacort) treatment2,3, the effects of which can be highly variable between patients. There is also considerable inter-patient variability in disease onset and progression4. This presents a significant challenge to clinicians in counselling patients and threatens to mask the benefits of novel treatments, and confound the results of clinical trials.

It has long been hypothesized that genetic variations at loci independent of dystrophin (that is, genetic modifiers) are responsible for unexplained variability in the progression of muscle weakness and response to therapies in patients with DMD. The first disease modifying gene to be identified in DMD patients, osteopontin (SPP1), was reported in 2011. A single nucleotide polymorphism (SNP) in SPP1, resulting in reduced gene expression, was associated with greater muscle weakness and earlier loss of ambulation (LoA)5. The mechanism underlying this effect on DMD phenotype has not yet been determined, but SPP1 expression is known to affect muscle regeneration6 and is upregulated in DMD patients7. Importantly, when stratifying cohorts based on SPP1 genotype, the number of patients required to detect a significant difference in a clinical trial setting is reduced by roughly 75%. More recently, LTBP4 was found to influence the age at which patients with DMD became non-ambulant via modulation of the TGF-β signalling pathway8,9. The modifier effect on LoA has since been replicated for both of these genes in a large patient cohort, but only when the cohort was stratified for both ethnicity and corticosteroid treatment, highlighting the difficulty associated with identifying genetic modifiers.

Interestingly, both SPP1 and LTBP4 map to the TGF-β pathway, a key driver of failed regeneration and the development of fibrosis in DMD (ref. 10), highlighting the potential for genetic modifiers to reveal molecular pathways which drive the dystrophic pathology. The ongoing identification of modifier genes is therefore of considerable importance as they contribute to our understanding of the pathological mechanisms that underpin DMD, and will have a major influence on future clinical trial design.

In skeletal muscle, the sarcomeric α-actinins are the major components of the Z-line where they bind and crosslink the actin thin filaments. α-Actinin-2 is expressed in all muscle fibres, but the highly homologous α-actinin-3 isoform is expressed only in fast, glycolytic fibre types. Importantly, there is a common null polymorphism (R577X, rs1815739) in the gene coding for α-actinin-3 (ACTN3), resulting in complete absence of α-actinin-3 in homozygous individuals (ACTN3 577XX, 16% of the global population and 18% of Caucasians)11. α-Actinin-3 deficiency is detrimental to sprint and power performance in both elite athletes12,13 and the general population14,15,16. Conversely, α-actinin-3 deficiency is associated with increased endurance performance in some athlete cohorts13,17, and improved response to resistance training14. Actn3 knockout (KO) mice mimic the phenotype seen in α-actinin-3 deficient humans; Actn3 KO mice have reduced muscle mass and strength18, but display increased endurance capacity, fatigue resistance and response to training19,20.

Actn3 KO mice do not exhibit a change in fibre type distribution at baseline, but the fast 2B fibres, which would usually express α-actinin-3, display a shift towards the properties classically associated with slower fibre types including; reduced fibre diameter18, increased oxidative metabolism18,21,22, slowed relaxation from contraction23 and an increased recovery from fatigue19. The mechanism responsible for this shift in fast-to-slow properties is likely because of a combination of metabolic and signalling changes in the absence of α-actinin-3. Specifically, we have identified increases in glycogen storage (because of a reduction in glycogen phosphorylase activity)22 along with increased calcineurin activity in Actn3 KO muscle20, which together promote greater oxidative metabolism and a fast-to-slow fibre type conversion in skeletal muscle.

It is clear that ACTN3 genotype significantly influences muscle function in both elite athletes and healthy individuals and hence may also be capable of modifying muscle function in DMD patients. Slower, more oxidative fibres are relatively spared from degeneration in DMD (ref. 24). In addition, calcineurin overexpression in mdx mice has been demonstrated to ameliorate the dystrophic phenotype25,26. Taken together these data led us to hypothesize that ACTN3 is capable of acting as a genetic modifier of DMD, and that the shift towards slower muscle metabolic properties associated with α-actinin-3 deficiency may have a protective effect against the pathogenesis of DMD. Here we show that the common null polymorphism (R577X) in ACTN3 results in significantly reduced muscle strength and a longer 10 m walk test time in young, ambulant patients with DMD. Using an Actn3 KO mdx (double KO) mouse model, we show a similar reduction in muscle strength, but protection from stretch-induced eccentric damage with age. Mechanistically, α-actinin-3 deficiency triggers an increase in oxidative muscle metabolism through activation of calcineurin, which likely confers the protective effect. This work therefore suggests that α-actinin-3 deficiency reduces muscle strength performance, but ameliorates the progression of dystrophic pathology.


ACTN3 genotype modifies strength in ambulant DMD patients

To assess muscle function in DMD, we analysed baseline data on a cohort of DMD patients (n=272) enroled in the Cooperative International Neuromuscular Research Group (CINRG) DMD natural history study (DNHS). We stratified this cohort to include steroid treated, ambulant, (young) 6–10 year old (n=61) and analysed quantitative muscle testing (QMT) and timed functional testing (10 m walk velocity); this approach is considered to provide the most sensitive and reliable phenotype to assess genetic modifiers27.

At baseline, ACTN3 genotype had a significant effect on both isolated muscle strength (grip QMT, knee and elbow extensor QMTs) and overall muscle function (10 m walk test). In all cases, the ACTN3 577X allele was associated with poorer muscle performance; ACTN3 577RX patients display significantly less strength across the QMTs and took significantly longer to complete the 10 m walk test compared with patients with ACTN3 577RR genotype. Similarly, patients with the ACTN3 577XX genotype show a trend for reduced muscle power output across all outcome measures in the cohort (Table 1).

Table 1: Baseline CINRG natural history cohort analysis.

Young dKO mice display reduced strength

To explore the ACTN3 genotype effect observed in DMD patients, we crossed Actn3 KO mice18 with the mdx mouse model of DMD, to create a double knockout model (dKO) lacking both α-actinin-3 and dystrophin. In agreement with our observations in ambulant DMD patients, muscles from young dKO mice (aged 8 weeks) display significantly reduced force producing capacity compared with mdx controls (Fig. 1a), which is maintained when correcting for the reduced size of the dKO muscles (Fig. 1b). Interestingly, both mdx and dKO muscles showed increased recovery from fatigue compared with WT (Fig. 1c), but we saw no difference between mdx and dKO. We saw no difference in the hill coefficient or twitch time to peak between mdx and dKO, but did see an increased half-relax time in dKO compared with mdx, indicating slowed relaxation following contraction (Table 2; Supplementary Fig. 1A–C). Dystrophic muscle is known to be vulnerable to stretch-induced damage28, and both mdx and dKO muscles are injured following a series of 20% eccentric stretches (Fig. 1d). We examined this phenotype further by inducing eccentric contractions in vivo via a downhill running protocol, using Evans blue dye (EBD) to mark injured fibres29. We saw a significantly increased number of EBD-positive fibres in dKO muscles (Fig. 1e), although this may be a product of the increased endurance capacity associated with α-actinin-3 deficiency20. A representative image of skeletal muscle following downhill run shown in Fig. 1f.

Figure 1: Baseline muscle physiology from 8 week old mice.
Figure 1

(a) dKO muscles produce 33% less force than mdx controls (mdx - 204.9 mN, dKO - 138.3 mN, P<0.001). (b) When corrected for cross-sectional area, dKO muscles produce significantly less maximum specific force than mdx. (c) Both mdx and dKO show significantly greater recovery from fatigue than WT, but no difference was observed between mdx and dKO. (d) dKO muscles suffer slightly less damage than mdx controls following a series of 6 20% eccentric contractions (mdx 45% drop in force following eccentric contractions, dKO 38%, P=0.08). A subset of the WT EDL muscle physiology data was previously published in Hogarth et al.43 (e) A higher percentage of gastrocnemius muscle fibres are EBD-positive following a downhill run in dKO mice than mdx. (f) Representative cross-section from a dKO gastrocnemius following downhill run. EBD positive fibres are shown in red and wheat germ agglutinin (Green) was used to delineate the fibre border. Scale bar indicates 500 μm. Data shown as mean±s.e.m., One-way ANOVA, *P<0.05, **P<0.01, ***P<0.001. WT n=11, mdx n=16, dKO n=11.

Table 2: Physiological properties of isolated EDLs from young WT, mdx and dKO mice.

α-Actinin-3 deficiency ameliorates mdx disease progression

To determine the influence of α-actinin-3 deficiency on the progression of the dystrophic pathology, we analysed muscle from aged (12 month) mice. Similar to our findings at baseline (8 week old mice), ex vivo EDL muscles of dKO mice produced less force than mdx (Fig. 2a), even when corrected for cross sectional area (Fig. 2b). The half-twitch relaxation time was also increased in dKO (Table 3). Importantly, aged dKO muscles demonstrated a significant reduction in force deficit following eccentric contraction compared with mdx controls (Fig. 2c). Aged dKO muscles also show considerably greater recovery from fatigue than mdx (Fig. 2d). Given that there was no difference in either parameter at 8 weeks, these findings suggest that α-actinin-3 deficiency protects against susceptibility to muscle damage with age. We sought to replicate these findings in the TA, using an in situ protocol, which arguably mimics muscle physiology better than the ex vivo EDL technique, and again saw reduced absolute force (Fig. 2e), maximum specific force (Fig. 2f), and decreased susceptibility to eccentric damage (Fig. 2g) in dKO compared with mdx.

Figure 2: Muscle physiology from 12 month old mice.
Figure 2

(ad) Ex vivo EDL muscle function. (a) dKO muscles produce 27% less force than mdx controls (mdx – 171.0 mN, dKO – 126.2 mN, One-way ANOVA, P<0.001). (b) When corrected for cross-sectional area, dKO muscles produce significantly less maximum specific force than mdx. (c) dKO muscles suffer less damage than mdx controls following a series of three 15% eccentric contractions (mdx - 71% drop in force following eccentric contractions, dKO - 47%, One-way ANOVA, P<0.01). (d) dKO show significantly greater recovery from fatigue compared with WT, and mdx. (e,f) In situ TA muscle function replicates the phenotype seen in the EDL. (e) dKO muscles produce 25% less force than mdx controls (mdx - 1613 mN, dKO-1221 mN, One-way ANOVA, P<0.01), (f) After correction for cross-sectional area, dKO show reduced specific force compared with mdx. Both are significantly reduced compared with WT. (g) Both mdx and dKO muscles are significantly injured compared with WT by eccentric contractions of increasing strain (Multiple T-test, FDR 1% #P <0.01), but dKO muscles suffer less damage than mdx between 25-30% LO (0–35%; mdx – 80% drop in force following eccentric contractions, dKO 65%, Multiple T-test, FDR 1%, P<0.05). Data shown as mean±s.e.m., One-way ANOVA, *P<0.05, **P<0.01, ***P<0.001, WT n=5, mdx n=6, dKO n=6.

Table 3: Physiological properties of isolated EDLs from aged WT, mdx and dKO mice.

To understand the phenotypes described above, we studied the TA histopathology of mdx and dKO mice (Fig. 3a). We observed a significant reduction in necrosis (mdx=10.7%, dKO=4.7%, Fig. 3b) and an increase (11%) in centrally nucleated fibres in dKO muscle compared with mdx (mdx=71.8%, dKO=79.2%, Fig. 3c). We also examined isolated intact single fibres from the EDL of WT, mdx and dKO mice for altered branching profiles (Fig. 3d). Fibre branches are known to accumulate over time as a marker of muscle damage in mdx mice30. Fibres isolated from dKO showed a small reduction in the number branched compared with mdx (Fig. 3e), but we observed a drastic reduction in the complexity of branching in dKO as only 18% of fibres contained four or more branches, compared with 74% of mdx (Fig. 3f).

Figure 3: Muscle pathology from aged mdx and dKO mice.
Figure 3

(a) Hematoxylin and eosin (H&E) stained TA sections from WT, mdx and dKO mice. Scale bar indicates 100 μm. (b) dKO muscles showed a significant reduction in total necrotic area compared with mdx (mdx – 10.7% versus dKO – 4.7%). (c) Both mdx and dKO show an increase in centrally nucleated fibres compared with WT, and dKO show a further increase compared with mdx (dKO – 79% versus mdx 71%, P<0.05). Data shown as mean±s.e.m., One-way ANOVA, *P<0.05, **P<0.01, ***P<0.001. WT n=11, mdx n=12, dKO n=11. (d) Individual fibres were isolated from 12 month old EDLs to assess fibre branching. The left hand panel shows an entire intact fibre from mdx with a branch which originates from the main body of the fibre which re-joins at the mid-belly of the fibre (indicated by arrows). The right hand panels show higher magnification examples of fibre branching. Scale bar indicates 100 μm. (e) Almost all fibres isolated from mdx (99%) and dKO (89%) are branched. (f) However, mdx show a higher number of branches per fibre than dKO; 74% of mdx fibres have 4 or more branches compared with 18% of dKO. Fibre counts are pooled (n=3 mice per genotype) with 600 fibres analysed per genotype.

ACTN3 genotype modifies disease progression in DMD patients

Given that α-actinin-3 deficiency ameliorates disease progression in mdx mice, we tested the effect of ACTN3 deficiency against the progression of DMD in the CINRG DNHS cohort by analysing LoA and repeated measures of grip QMT over time. Genotype-specific Kaplan-Meier plots for LoA in 266 CINRG Duchenne Natural History Study participants show that heterozygote (RX) participants suffered 1-year to 2-year earlier LoA (Fig. 4a): median age at LoA in these participants was 11.7 years (95% CI 11.0–13.0), but no difference was observed between RR (12.5 years, 95% CI 11.1–14.0) and XX (13.0 years, 95% CI 11.9–14.0). The same pattern was detected when restricting the analysis to European ancestry: median age at LoA in the RX genotype was 12.0 years (95% CI 11.0–14.0), versus 13.0 (95% CI 11.1–18.0) in RR and 14.0 (95% CI 12.0–14.5) in XX. Taking the RR genotype as reference and performing a Cox regression, including glucocorticoid (GC) treatment as a covariate, the RX genotype was significantly associated with risk of earlier LoA, with an odds ratio (OR) of 1.44 (95% CI 1.01–2.07, P=0.044). In the smaller European ancestry sub-cohort, there was a trend in the same direction using the same statistical test: OR for the RX genotype was 1.64 (95% CI 0.93–2.90, P=0.089). We genotyped the Padova DMD cohort for rs1815739 (n=102 successfully genotyped), and again observed an earlier median LoA in RX (10.4 years, 95% CI 9.92–11.6) than RR (11.0 years, 95% CI 10.32–12.7, Supplementary Fig. 2), but this difference was not significant in a Cox regression model including GC treatment. Median age at LoA in the XX group was 10.2 years, 95% CI 9.8 – undetermined upper limit because of a low number of individuals with this genotype (n=10). To test concurrent effects of ACTN3 genotype, previously known genetic modifier genotypes (SPP1 rs28357094 and LTBP4 rs10880), and GC treatment, we devised a Cox regression model including 297 participants of self-identified European ancestry, from both the CINRG DNHS and Padova Cohort, for whom all these data were available. In this model, the effect of the ACTN3 RX genotype was detrimental (OR 1.45, 95% CI 1.05–2.00, P=0.022), while the homozygous XX genotype was not (Supplementary Table 1). The strong effect of GCs in delaying LoA was confirmed by this analysis, which showed a 3.1 year delay of LoA with treatment (OR 0.23, 95% CI 0.16–0.31, P<0.0001, see Supplementary Table 1), stressing the importance of including GC treatment in the statistical model for genotype effects.

Figure 4: Longitudinal analysis of the CINRG cohort.
Figure 4

(a) Kaplan-Meier survival analysis for age at loss of ambulation (LoA) in 266 CINRG Duchenne Natural history Study participants. Heterozygous (RX) participants suffered 1- to 2-year earlier LoA with a median age of 11.7 years (95% CI 11.0–13.0), as opposed to 12.5 (11.1–14.0) in RR and 13.0 (11.9–14.0) in XX. (b) Longitudinal analysis of grip QMT in steroid-treated 6 to 10 year old DMD patients. They are not necessarily the same subjects throughout the 48 month period of testing. Some subjects only met the criteria in the middle of the study and others were only included in the analysis for a few time points. Error bars represent mean±95% CI.

We also examined grip QMT over a 4 year period in steroid treated 6–10 year olds using mixed effects linear regression (Fig. 4b). Similar to our findings at baseline, we see a reduction in strength associated with the X allele as RX individuals show a mean grip strength which is 0.471 lbs less than RR (95% CI 0.172–0.770, P=0.002) and 0.283 lbs less for XX individuals (95% CI 0.062–0.628, P=0.108). When we combined all genotypes, we did not see a difference in grip strength over time, suggesting that the dystrophic pathology counteracts the natural increase in strength one would expect during childhood development between these two ages. However, we did see a significant interaction between ACTN3 genotype and time (P=0.021). This suggests that ACTN3 genotype significantly influences grip strength over time, although the magnitude of this influences was not evaluated at the individual genotype level, but instead as a single genotype factor.

Increased calcineurin activity ameliorates pathology in dKO

Slow fibres are largely spared in the pathogenesis of DMD (ref. 24), and forced fast-to-slow fibre type conversion via the overexpression of calcineurin ameliorates the dystrophic phenotype in mdx mice25,26. The exact mechanism by which slow fibres are resistant to dystrophy is unclear, but may be the result of one or more of the following properties - smaller fibre diameter, increased utrophin expression or a preference for oxidative metabolism. We sought to test each of these possible explanations for the protective effect of α-actinin-3 deficiency on disease progression in mdx mice.

We cut sections from the mid-belly of the quadriceps and co-labelled with antibodies against the different myosin heavy chain (MyHC) isoforms to investigate fibre size and type distribution (Fig. 5a). At 12 months, both mdx and dKO showed a higher frequency of small fibres compared with WT (Fig. 5b). While this can be attributed in part to the presence of small regenerating fibres in dystrophic muscle, fibre branches are also likely included in this analysis as these are difficult to identify in cross-section and hence are included in the counts. We observed a significant reduction in overall fibre size in dKO muscle compared with WT (Fig. 5b), which is likely a product of reduced 2B fibre size in these animals (Fig. 5c). However, we did not observe a shift in fibre type as the relative proportions in MyHC isoform were unchanged (Fig. 5d).

Figure 5: Fibre size is reduced in dKO mice.
Figure 5

(a) Representative image of fibre typing in WT quadriceps. Sections cut from the midbelly of 12 month old male quadriceps were stained with antibodies against MyHC Type 1 (green), 2A (blue) and 2B (red), while 2X fibres were left unstained. A488 conjugated wheat germ agglutinin was used to mark membranes to delineate the individual fibres (Green). Scale bar indicates 500 μm. (b) Fibre size frequency distribution for all quadriceps fibres (Approx 7,000 per quadriceps). The mean fibre size was reduced in dKO compared with mdx (1781±158 μm2 versus 1223±242 μm2, P<0.05). (c) Frequency distribution for all 2B fibres in the quadriceps. Mean 2B fibre size is reduced in dKO compared with WT (1950±213 μm2 versus 1670±267 μm2, P<0.05). (d) Individual fibre types presented as a percentage of total fibre number show no shift in fibre type proportion across all the genotype groups. Data shown as mean±s.e.m., WT n=6, mdx n=7, dKO n=6.

At a protein level, there is a significant increase in the level of α-actinin-2 in dKO (Fig. 6a,b); this is a characteristic of α-actinin-3 deficient muscle in Actn3 KO mice, and likely represents a compensatory upregulation of this closely related protein21,31. In addition, we have previously observed a significant increase in calcineurin activity in both α-actinin-3 deficient human and mouse muscle, and demonstrated that this is a likely mechanism for the slower twitch relaxation time, increased recovery from fatigue, enhanced response to endurance training and shift towards an oxidative metabolic phenotype in Actn3 KO mice20. Calcineurin is a calcium sensitive phosphatase known to signal fast-to-slow fibre type transition in skeletal muscle32. Here we show a marked (2-fold) upregulation in the expression of regulator of calcineurin 1.4 (RCAN 1.4) (which is indicative of increased calcineurin signalling) in dKO mice compared with control mdx (Fig. 6a,b); however this was not associated with an increase in the expression of utrophin or a shift in fibre type (based on MyHC isoform) at baseline (Supplementary Fig. 3).

Figure 6: Relative protein expression in dKO muscle compared to mdx.
Figure 6

(a,b) dKO muscle at 12-months of age show a compensatory upregulation of α-actinin-2 for the loss of α-actinin-3 and a 2.4-fold upregulation in RCAN1.4, but no change in the level of utrophin. (c,d) No significant differences in the expression of total and phosphorylated ACC, and total and phosphorylated AMPK were observed, but dKO mice did show a trend for increased expression of each. (e,f) dKO muscle shows an increase in oxidative metabolism as evidenced by significant upregulation in ATP synthase (ATPase), succinate-Q oxidoreductase (Complex II), cytochrome-c oxidoreductase (Complex III) and cytochrome c oxidase (Complex IV). Graphs b,d and f represent relative OD levels normalized to actin and mdx. Data shown as mean±SEM, One-way ANOVA, *P< 0.05. mdx n=4, dKO n=4. Full-length blots are presented in Supplementary Fig. 6.

AMP-activated protein kinase (AMPK) is another key regulator of muscle metabolism and also plays a role in the conversion of fast muscle fibres to a slow fibre phenotype33. Pharmacological stimulation of AMPK in mdx mice causes a shift towards oxidative metabolism and ameliorates the dystrophic pathology34,35. On this basis, we examined the total and phosphorylated expression levels of AMPK and the co-regulated protein acetyl-CoA carboxylase (ACC) in mdx and dKO muscle and observed trend for increased AMPK and ACC phosphorylation expression at baseline (Fig. 6c,d), providing further novel evidence for a shift towards a more oxidative muscle metabolism in α-actinin-3 deficient mdx muscle.

Given the increase in two of the key regulators of oxidative metabolism (calcineurin and AMPK) we assessed the dKO mouse at baseline for changes in Pgc-1α mRNA expression and markers of oxidative phosphorylation. In dKO muscle we observed a 2-fold increase in Pgc1-α mRNA when normalizing mRNA expression to the geometric mean of four reference genes (One-way ANOVA, P=<0.01), with no obvious change in protein expression (Supplementary Fig. 4). We also see evidence for a shift in mitochondrial function as dKO muscle shows upregulation in the expression of ATP synthase (16%, ATPase), succinate-Q oxidoreductase (30%, Complex II), cytochrome-c oxidoreductase (18%, Complex III) and cytochrome c oxidase (44%, Complex IV) compared with mdx controls (Fig. 6e,f).


Recent advances in muscular dystrophy research have resulted in an increased number of potential therapies and subsequent clinical trials to treat DMD and slow disease progression36,37. While this is exciting, the detection of unequivocal therapeutic benefit in these trials has been challenging and they are not currently approved for use by patients. One reason for this lack of translation into clinical practice is because of the absence of clear positive outcomes from current clinical trial data38. Though this may be because of failed utility of the drug or treatment, the large inter-patient variability in response to many of these agents has made it difficult to draw conclusions (positive or negative) from many of these studies. It is increasingly recognized that the identification of genetic modifiers is vital to minimize the confounding effects of inter-patient variability in these trials. Here we present evidence that a common null polymorphism in the ACTN3 gene has a significant effect on muscle strength and function in young ambulant DMD patients. The ACTN3 577X allele was associated with significantly reduced muscle strength and poorer performance in the 10 m walk test. Interestingly, the ACTN3 577XX genotype is also associated with reduced 40 m sprint times in healthy adolescent males15, which mirrors our findings in DMD patients. Muscles from dKO mice also produce significantly less force than their mdx counterparts, but show increased recovery from fatigue. Taken together, these data strongly suggest that α-actinin-3 deficiency results in reduced power output in dystrophic muscle and that ACTN3 R577X genotype should be considered when evaluating quantitative muscle tests in DMD patients.

Susceptibility to stretch-induced damage is a well characterized phenotype in dystrophic muscle28,39,40, and it worsens as the disease progresses30. The young (8-week old) dKO mice show a greater percentage of EBD containing muscle fibres following a single downhill run. However, there was no difference in susceptibility to eccentric contraction damage when measuring isolated ex vivo EDL of young dKO compared with mdx control mice. This is an important comparison. In isolation the downhill run analysis would suggest that the absence of α-actinin-3 results in a larger number of damaged muscle fibres; however ex vivo analysis of EDL muscles suggest that there is no effect of genotype in muscle damage properties at 8 weeks of age. In this case, the in vivo approach of downhill running is likely confounded by the observation that Actn3 KO mice are able to run further and more effectively than WT mice20. The isolated EDL analysis removes the intrinsic aspect of Actn3 genotype-associated running performance from this analysis and allows us to observe the primary effect of α-actinin-3 deficiency. Taking both data into account, it is reasonable to assess that dKO muscle shows a similar susceptibility to stretch-induced damage compared with mdx at 8 weeks.

At 12 months old however, α-actinin-3 deficiency exhibits a significant protective effect against stretch-induced damage, with dKO mice showing a 34% reduction in force deficit following eccentric contraction. Given that we saw no difference between dKO and mdx at 8 weeks, and that susceptibility to stretch-induced damage is known to increase with age, this suggests that α-actinin-3 deficiency alters the mdx pathology over time. Because this is an important finding, we re-tested the phenotype in the TA using an in situ muscle function assessment which some consider to be the gold-standard for examining functional differences in muscle performance in rodents. Again we saw a significant amelioration in the susceptibility to stretch-induced damage in dKO muscle compared with mdx, confirming our findings from the EDL. Finally we looked at fibre branching morphology, as branched fibres are also known to accumulate with disease progression in dystrophic muscle41 and correlates with susceptibility to stretch-induced damage42. The observed reduction in branching complexity in dKO mouse muscle at 12 months directly correlates with the decreased susceptibility to eccentric damage. In combination, these data provide strong evidence to suggest that dystrophic progression is slowed in α-actinin-3 deficient muscle.

While we show evidence that α-actinin-3 deficiency ameliorates disease progression in mdx mice, examining an effect of ACTN3 on progression in DMD patients is much more challenging. ACTN3 genotype has a significant effect on LoA in the CINRG cohort, but this is largely driven by a reduced ambulation in heterozygous (RX) patients compared with both homozygous groups. Biologically, this is difficult to explain, but we have recently shown evidence for haploinsufficiency associated with ACTN3 (ref. 43), which may explain this phenomenon. Preliminary analysis shows that Actn3+/− mdx muscles display reduced force (comparable to dKO), but not the protection against stretch-induced damage seen in dKO muscle (Supplementary Fig. 5). Although further investigation is required, it appears that loss of a single ACTN3 allele does not drive muscle adaptation enough to ameliorate the progression of the dystrophic phenotype in mdx mice and hence heterozygous mice presumably suffer the disadvantage associated with reduced α-actinin-3 expression (that is, reduced strength), but do not gain any of the associated advantageous phenotypes (protection of muscle damage).

In human populations, ACTN3 association studies may also be confounded by population stratification, as the null allele is more frequent in non-European populations (1000 Genomes), who might also present a different DMD phenotype severity because of standard of care disparity or different genetic background. Age at LoA in the heterozygous genotype was earlier in both the CINRG European ancestry sub-cohort, and the Padova cohort (also of European ancestry). In the latter, the XX genotype behaved more similarly to RX (early LoA) rather than to RR as in the CINRG cohort, but the number of XX individuals was low (n=10), making this estimate scarcely accurate. In the merged European populations (n=297), the association of earlier LoA with the heterozygous genotype proved significant independent of the effects of other known genetic modifiers and corticosteroid treatment. When the LoA analysis was restricted to European ethnicity, XX individuals showed prolonged ambulation of 1 year on average compared with RR, but this difference was not significant. The observation of a detrimental effect of the heterozygous, but not of the null homozygous genotype, was unexpected. LoA is a more complex phenotype than sheer muscle strength, as ambulatory function involves compensatory mechanisms, relative involvement of different muscle groups, and joint contractures. Thus, it could be that the metabolic and fibre type changes induced by ACTN3 deficiency at various levels affect the balance between these variables in a complex manner. Further genotyping of larger cohorts is warranted to strengthen this conclusion.

We made a similar observation when analysing grip strength over time, as ACTN3 genotype had a significant effect, but we lacked the statistical power to compare individual genotypes. However, scrutinizing the results presented in Fig. 4b suggests that XX individuals show a favourable gradient relative to RR, indicating the α-actinin-3 deficiency may protect against the loss of strength over time. It is clear from both the LoA and longitudinal grip strength analyses that any effect of ACTN3 on the progression of DMD is subtle and hence large scale cohort analysis will be required to determine the effect with any certainty. However, we do present strong evidence indicating that ACTN3 genotype modifies muscle strength in DMD and therefore should be included as a covariate in the analysis of functional outcomes for all future clinical trials.

Slow fibres are relatively spared from degeneration in both DMD biopsies24 and mdx mice28; understanding the basis of this ‘protective effect’ of slow fibres could provide important insights into potential therapies for DMD. Promoting fast-to-slow fibre type conversion by calcineurin overexpression25,26 or chronic pharmacological activation of AMPK (refs 34, 35) in mdx mice ameliorates the dystrophic pathology and protects against stretch-induced damage. Both interventions result in a decrease in fibre size, increased utrophin expression and a shift towards oxidative metabolism; each of these characteristic properties of slow fibres may modify the dystrophic phenotype. dKO muscles show a reduction in overall fibre size, which is a product of smaller 2B fibres as these are the major constituent of the quadriceps and the only fibre type which expresses α-actinin-3 (ref. 44). However, we did not see a change in the expression of utrophin, but this is consistent with the lack of fast-to-slow fibre type conversion in dKO muscle. Interestingly, dKO muscle displays a physiological increase in calcineurin (RCAN1.4) and AMPK signalling, which result in a similar phenotype to the aforementioned models, including; reduced force production, increased recovery from fatigue and protection against stretch-induced damage. In line with these studies, we see a shift in the contractile properties of dKO muscle towards a slower twitch phenotype, which is accompanied by increases in markers of oxidative metabolism as demonstrated by increased Pgc1-α mRNA expression (Supplementary Fig. 4) and upregulated ATP synthase, complex II, III and IV protein expression.

We have previously demonstrated that α-actinin-3 deficiency results in a shift toward a slow-twitch, oxidative metabolic phenotype18,21, which is known to be impaired in mdx muscle45,46 and contributes to pathology by compromising skeletal muscle integrity47. Hence, it is likely that the shift towards oxidative metabolism associated with α-actinin-3 deficiency underlies the protective effect observed in dKO mice. Previous studies have shown that manipulation of either calcineurin25,31 or AMPK signalling35,36 ameliorates the pathology of mdx mice. But, in both cases, the approaches used increased activity several fold above wild type levels; here we show that physiological alterations in these pathways by a single genetic variant is enough to have a significant effect. This has important implications for the management of DMD patients moving forward; many current treatment strategies including mysotatin inhibition aim to ameliorate progression by inducing muscle hypertrophy to counteract muscle weakness48, but our results from α-actinin-3 deficient muscle suggest that pharmacological and exercise interventions which promote a shift towards slow, oxidative metabolism and reduced fibre size may be more beneficial in the long term.

Metabolic dysfunction is a common feature across many different genetic muscle diseases7,49 and the age-related decline in muscle function50,51. Hence, we believe that the genetic modifier effect of ACTN3 is not limited to DMD, but is likely to be more broadly applicable to a wide cross-section of muscle pathologies.


Statistical analysis of the CINRG and Padova human cohorts

We received approval from ethical standards committees on human experimentation (institutional or regional) for any experiments using human subjects, and written informed consent was obtained from all patients (or guardians of patients) participating in the study (consent for research), as previously reported for the CINRG (refs 5, 52) and Padova5 cohorts. Velocity and QMT values from the CINRG natural history cohort were tested for normality using the Shapiro–Wilk normality test and visual inspection of histograms. All QMT values were found to be skewed; therefore all analyses were performed on square root transformed QMT values. Mean values were compared among ACTN3 genotypes via one-way analysis of variance with post-hoc pair-wise comparisons done and adjustment of P-values for multiple comparisons using the Šidák method. P values≤0.05 were considered statistically significant. Muscle biopsies from this cohort were not available for further molecular analysis.

Further analysis of velocity and QMT values over time were performed using mixed effect linear regression models. The models were fit with velocity or QMT as the dependent variable, genotype and time as fixed effects and subject with a random intercept and slope.

Loss of independent ambulation (LoA) in the CINRG Duchenne Natural History Study (DNHS) was defined as continuous wheelchair use, confirmed by inability to walk 10 m unassisted. Genotyping was performed by a TaqMan genotyping assay. The effect of ACTN3 genotype on LoA was studied in a time-to-event statistical framework, with age as a time variable and LoA as event, and censoring participants who were still ambulatory at last follow-up. Genotype effect on LoA was tested by Cox regression, with glucocorticoid (GC) treatment as a covariate (treatment for at least 1 year while ambulatory versus untreated or treated <1 year), and modelling genotype as a 3-way categorical variable (RR, RX or XX), as an additive effect (number of copies of the X allele), or as a dominant effect (no copies versus at least 1 copy of the X allele). This statistical analysis was run in R version 3.2.1 (‘survival’ package). Minor allele frequency for rs1815739 varies between ethnicities, and as there are differences in phenotype between different races and ethnicities in the CINRG-DNHS cohort, this could lead to a population stratification bias. Therefore, analyses were run both in the whole (multi-ethnic) CINRG-DNHS cohort (n=266), and in a sub-cohort of European and European American ancestry, controlled for population stratification by multidimensional scaling analysis (n=114)52. We also aimed to replicate the results from the CINRG-DNHS in a second cohort of DMD patients. To investigate this, the same methodological approach described above was used to analyse the effect of ACTN3 genotype on LoA in the Padova cohort of DMD patients (n=102).


Mdx (C57BL/10ScSn-Dmdmdx/J) mice were obtained from Jackson Laboratories (Bar Harbor, ME, USA). The Actn3 knockout (KO) line created in this laboratory21 was backcrossed onto the C57BL/10 background for 10 generations before being crossed with the mdx line to produce mice lacking both α-actinin-3 and dystrophin (dKO). All animal experiments were approved by the Childrens Medical Research Institute (CMRI) and Murdoch Childrens Research Institute (MCRI) animal ethics committees and performed according to their prescribed guidelines. Experiments were performed on male animals at 2 timepoints; 8±1 weeks (baseline) and 12±1 months (aged).

Muscle physiology assessment

Downhill run was performed in order to induce muscle damage in vivo using a modified protocol53. Briefly mice were forced to run downhill in the presence of Evans blue dye (EBD) injected intraperitoneally 30 min before performing the downhill run protocol. Following EBD injection mice were placed on an Accupacer treadmill (Columbus Instruments) set at a 15° decline and run for 10 min at a speed of 15 m per min. Mice were euthanized 24 h after the downhill run, and all hindlimb muscles were harvested. To visualize muscle damage, 8 μm sections were cut from the midpoint of the gastrocnemius muscle. These were fixed with 4% paraformaldehyde at 27° for 10 min and then incubated with Alexa488-conjugated wheat germ agglutinin (W11261, Life Technologies, 1:200) for 1 h to mark the boundaries between fibres. EBD inclusion was imaged using fluorescent microscopy, at 620 nm (excitation) and 680 nm (emission). All Fibres were then counted to determine the % of dye inclusion per cross section.

Ex vivo Extensor digitorum lognus (EDL) muscle physiology was performed using WT, mdx and dKO mice. The EDL was carefully dissected from the lower hindlimb and tied by its tendons to a force transducer (Fort series, World Precision Instruments) at one end, and a linear tissue puller (University of New South Wales) at the other using silk suture (Deknatel 6.0). The isolated muscle was placed in a bath continuously perfused with Krebs solution, composed of (in mM) 4.75 KCl, 118 NaCl, 1.18 KH2PO4, 1.18 MgSO4, 24.8 NaHCO3, 2.5 CaCl2 and 10 glucose with 0.1% fetal calf serum and was continuously bubbled with carbogen (95%O2, 5%CO2) to maintain pH at 7.4.

The muscle was stimulated by delivering a supramaximal current between two parallel electrodes in the bath using an electrical pulse generator (A-M Systems). The optimal length (LO) was determined as the muscle length at which maximum twitch force was generated prior to experimentation and set as the baseline.

A force frequency curve was obtained by delivering 500 ms stimuli of different frequencies (2, 15, 25, 25, 37.5, 50, 75, 100, 125 and 150 Hz) and measuring the force produced during each stimulation. A 30 sec rest was allowed between each to mitigate the effects of fatigue. A curve relating to the muscle force and stimulation frequency was fitted to the data. From the fitted curve the following parameters were obtained; maximum force (Pmax), Hill coefficient and twitch to tetanus ratio.

Following generation of the force frequency curve, the muscle was subjected to a series of eccentric stretch contractions. Two distinct protocols were performed to ensure adequate muscle damage was achieved at each time point. We have previously shown that a 15% stretch in young (6-8 week old) mdx mice is insufficient to induce muscle damage30. Therefore at 8 weeks of age, muscles were stimulated for 4 sec at 100 Hz, and at t=250 ms when the maximum isometric force was reached, and stretched to 20% longer than LO at a constant speed of 5 mm per sec. The muscle was held at this extended length for 2 sec before being returned to LO at 5 mm per sec. This process was repeated six times, with a 3 min interval between each eccentric contraction. Following the final stretch, the muscle was allowed to recover for 10 min before a second force frequency curve was generated. The Pmax following the eccentric contractions was obtained from this and subtracted from the original Pmax to give the raw force deficit. Finally, the raw force deficit was expressed as a percentage of the pre-stretch Pmax for analysis. This protocol was altered for muscles from aged mdx mice because of the more advanced disease; muscles were stimulated for 5 sec at 100 Hz, and stretched to 15% longer than LO at a constant speed of 2 mm per sec. The muscle was held at this extended length for 2 sec before being returned to LO at 2 mm per sec. This process was repeated three times at 5 min intervals and the muscle was allowed to recover for 10 min before the force deficit was calculated.

A separate set of muscles were used to analyse the recovery from fatigue. Following generation of a force frequency curve and after a 10 min rest, muscles were subjected to the following fatigue protocol; repeated 1 sec tetani at 100 Hz every 2 sec for a period of 30 sec. To track the recovery, the force produced by short (250 ms) 100 Hz tetani was recorded at 30 sec, 1, 2, 3, 5 and 10 min post fatigue. The force produced during each of the 100 Hz tetani during the fatigue protocol and subsequent recovery was recorded and expressed relative to the pre-fatigue force.

In situ assessment of the tibialis anterior (TA) was performed in aged (12 month old) WT, mdx and dKO mice (n=5–7 mice per genotype) using the Arora Scientific 1300A whole mouse test system and 701C stimulator. Briefly, mice were anaesthetized using isoflurane inhalation (0.6 ml per min) and placed on a 37oC heated platform, the distal tendon of the TA was surgically isolated and the knee joint exposed. Surgical silk (Silicon coated suture silk 5/0, Covidien) was used to secure the TA tendon to the force transducer (Model 809B in situ test apparatus), the foot and knee were clamped in place for stability. Maximum tetanic force (mN), specific force (mN per mm2) and the degree of contraction-induced damage (% force loss) were determined, as previously outlined in Percival et al.54 with minor modifications. Briefly, the TA muscle was adjusted to an optimum length (Lo) to produce maximum twitch force (Pt), and the fibre length (Lf) was calculated using the correction value of 0.6 (Lf=Lo × 0.6). The TA was then stimulated every 2 min at increasing frequencies (5–250 Hz) to generate force–frequency curves. Maximal tetanic force (Po) was typically achieved at 150 Hz. Both Lo and TA mass were recorded and used to determine Pt, Po and specific tetanic (sPo) force for each muscle.

The TA muscle from each subject underwent a series of lengthening contractions of progressively increased strain (0–35%). Strain is the percentage increase in length beyond the optimal Lf. Muscles were maximally stimulated (7 mA, at 150 Hz) for 150 ms at Lo to achieve maximal isometric tension, immediately followed by 200 ms of stimulation during the application of a 5% increase in length (ranging from 0 to 35%) beyond Lf. Stretch was applied at a rate of 2 fibre lengths per sec with 30 sec intervals between each stretch. The force (Po) generated immediately prior to the initiation of the subsequent lengthening contraction was recorded and normalized to the starting force to calculate % force generated.

Tissue collection

Mice were euthanized via cervical dislocation. The skin was removed from the hindlimb and individual muscles were dissected out, with overlying fascia and adipose tissue discarded. The wet weight of the isolated muscles was recorded immediately upon excision to minimize the effect of evaporation on the measurement. Following this, the individual muscles were covered in a cryo-preservation medium (TissueTek) and frozen in liquid nitrogen-cooled isopentane. Tissue was stored at −80° until use.

Muscle histopathohlogy and fibre morphology

Histological assessments were performed in the TA of 12 month old mdx and dKO mice (n=10–14 mice per genotype). Briefly, the TA of WT, mdx and dKO mice were removed and weighed before being frozen in liquid nitrogen cooled isopentane, samples were stored at −80 °C until use. The TA were cut through the mid-belly and 8 μm sections were collected and placed on Superfrost-Plus microscope slides (Thermo fisher Scientific). Hematoxylin and eosin (H&E) staining was performed as outlined previously55. Muscles were frozen in liquid nitrogen pre-chilled isopentane and stored at −80 °C until analysis. Muscles were cryo-sectioned at 8 μm and placed on a microscope slide. The sections were incubated in Haematoxylin (for 5 min, HHS32, Sigma Aldrich) and Eosin (for 2 min; HT110232, Sigma Aldrich) and the whole TA cross-section was imaged using a scanning light microscope (Leica Biosystems). Images were imported into ImageJ for analysis56. All histological analyses were performed according to the Treat-NMD preclinical standard operating procedures (SOPs) while blinded to genotype.

Fibre branching morphology was performed using individual fibres isolated from the EDL of WT, mdx and dKO mice (n=3 mice per genotype). The muscles were digested in Krebs solution (in mM): 1.2 NaH2Po4, 1 MgSO4, 4.83 KCl, 137 NaCl, 24 NaHCO3, 2 CaCl2, 10 Glucose, with 3 mg per ml collagenase IV (C5138, Sigma-Aldrich), which was bubbled with carbogen and incubated at 37 °C. After 30 min, the muscles were removed from the digesting solution, rinsed in Krebs and placed in a relaxing solution (in mM): 117 K+, 36 Na+, 1Mg2+, 60 HEPES, 8 ATP, 50 EGTA2−, with free Ca2+ of 10−7 M. Individual fibres were obtained by gently agitating the muscle with a pipette and their morphology was examined under a light microscope. Fibre morphological analyses were performed blinded to genotype and digital-photographic representations recorded for all fibres (mdx, n=272 fibres and dKO, n=608 fibres).

Myosin heavy chain profile

Transverse 8 μm sections were cut from the midpoint of the quadriceps muscle. These sections were blocked with 2% BSA for 10 min before being incubated overnight at 4 °C with an antibody against myosin heavy chain 2B (BF-F3, DSHB, University of Iowa, USA, 1:10 dilution) and Alexa488-conjugated wheat germ agglutinin (W11261, Life Technologies, 1:500). Following primary incubation sections were washed three times with PBS and re-blocked with 2% BSA for 10 min. Secondary antibodies, Alexa555 goat anti-mouse IgM (A-21426, Molecular Probes, 1:500) and Alexa 488 goat anti-rabbit IgG (A-11008, Molecular Probes, 1:500) were then applied for 2 h at room temperature. Sections were washed three times in PBS and blocked with AffiniPure fab fragment goat anti-mouse IgG (115-007-003, Jackson ImmunoResearch, 1:200) for 1 h. Immediately following this, sections were incubated with antibodies against slow myosin type 1 (MAB1628; Chemicon, 1:100) and myosin heavy chain 2A (SC71; DSHB, University of Iowa, used neat), covalently labelled with Alexa 488 and Alexa 350 respectively, with a Zenon labelling kit (Z25070, Invitrogen) for 2 h at room temperature. Finally sections were washed three times in PBS to remove any unbound antibody, fixed with 4% paraformaldehyde for 10 min and coverslips were mounted. These whole IHC-stained sections were imaged at × 40 using ProgRes camera and software (SciTech). The fibre diameter and number was analysed using MetaMorph software according to published protocols57.

Protein expression analysis

The snap frozen quadriceps from each mouse were ground using a liquid nitrogen-cooled mortar and pestle. Approximately 2 mg of the ground tissue was solubilized in 500 μl 4% SDS buffer containing 50 mM Tris, 10% glycerol, 50 mM DTT, bromophenol blue and protease inhibitor cocktail (Sigma-Aldrich). The concentration of total protein in each sample was assessed using a BCA protein assay kit (Thermo Fisher).

Up to 50 μg of protein lysate was loaded onto 4–12% Bis–Tris precast minigels (Life Technologies), separated by SDS–PAGE and transferred onto polyvinylidene fluoride membranes (Millipore). The membranes were incubated with antibodies against α-actinin-2 and -3 (gift from Alan Beggs, Children’s Hospital Boston), AMPKα (Total (5,831) and Thr172 (2,535) Cell Signalling, 1:1,000), Acetyl-CoA Carboxylase (ACC total (3,676) and Ser79 (11,818) Cell Signalling, 1:1,000), utrophin (DRP2-CE-S, Novocastra, 1:1,000), RCAN 1.4 (D6694; Sigma-Aldrich, 1:500), MitoProfile Total OXPHOS antibody cocktail (AB110413, Abcam, 1:2,000), COX IV (20E8; Molecular Probes, 1:1,000) and Pgc1α (AB3242, Merk Millipore, 1:1,000). α-Sarcomeric actin (A2172, 5C5, Sigma-Aldrich, 1:2,000), was used as a loading control, and after developing, membranes were stained with Coomassie Brilliant Blue (1610436, Sigma-Aldrich), and the expression of myosin was used as an additional loading control. Films were scanned using an Epson scanner, and the optical density of bands was computed using ImageJ software (NIH).

Quantitative real-time PCR (RT-qPCR)

Total RNA was isolated from 50 mg of mouse quadriceps tissue using TRIzol (Invitrogen) according to the manufacturer’s instructions. The RNA was resuspended into 50 μl DEPC treated water and purified and DNAseI treated using RNeasy Mini on-column clean-up (Qiagen). RNA quality and quantity was assessed using a 2100 Bioanalyser (Agilent Technologies) 6,000 RNA kit (Agilent Technologies) according to the manufacturer’s instructions. One microgram (1 μg) of total RNA was reverse transcribed using Super-Script III Reverse Transcriptase (Invitrogen), random pdN6 primers (Roche), 0.1 mM DTT (Invitrogen) and 10 mM dNTP (Invitrogen) in a 20 μl volume for 90 min at 50 °C on a Veriti 96-well thermocycler (Applied Biosystems). All cDNA was diluted in DEPC treated water (Bioline) prior to RT-qPCR. Diluted cDNA was aliquoted into working volumes of 10 μl and stored at −80 °C until use.

Reverse transcriptase quantitative PCR (RT-qPCR) was performed using standard curves generated from serially diluted plasmid constructs of each gene of interest as outlined in Thomas et al.58 Relative gene expression was determined using the geometric mean of four reference genes (Rer1, Rpl41, Rn18S, Actb) to normalize Pgc1α mRNA expression in mdx and dKO (Table 4). Absolute Pgc1α expression levels were determined based on the known DNA concentrations from the Pgc1α standard curve using our previously published method58. RT-qPCR was carried out using a Rotor-Gene 6000 (Qiagen) in a 20 μl reaction volume consisting of, 1 μl mouse cDNA, 10 μM of forward and reverse primers, × 1 MyTaq buffer (Bioline), 0.2 U MyTaq DNA polymerase (Bioline), 0.4 μl × 10 SYBR Green I (Life Technologies) and DNAse-free water. All samples and plasmid DNA were amplified in triplicate and a no-template-control (NTC) was included in each reaction. Amplification were performed with a 2 min denaturation step at 95 °C, followed by 35 cycles of 95 °C for 30 sec, 62–65 °C (Table 4) for 30 sec and 72 °C for 30 sec. Melt curve analysis was performed from 60–99 °C to assess amplification specificity.

Table 4: RT-qPCR primers and conditions.

Statistical analysis of animal data

The methods used for analysis of animal data are the same as those described for the analysis of velocity and QMT phenotypes in the human data, namely analysis of variance methods with post-hoc pair-wise comparisons where appropriate. This analysis was performed using GraphPad Prism software.

Data availability

All relevant data are available from the authors. The human cohort dataset is not publicly available, but can be obtained via formal request to the CINRG consortium (

Additional information

How to cite this article: Hogarth, M. W. et al. Evidence for ACTN3 as a genetic modifier of Duchenne muscular dystrophy. Nat. Commun. 8, 14143 doi: 10.1038/ncomms14143 (2017).

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


  1. 1.

    , & Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51, 919–928 (1987).

  2. 2.

    , , , & Report on the 124th ENMC International Workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids 2–4 April 2004, Naarden, the Netherlands. Neuromusc. Disord. 14, 526–534 (2004).

  3. 3.

    et al. Practice parameter: corticosteroid treatment of Duchenne dystrophy. Neurology 64, 13–20 (2005).

  4. 4.

    et al. Clinical heterogeneity of Duchenne muscular dystrophy (DMD): definition of sub-phenotypes and predictive criteria by long-term follow-up. PLoS ONE 4, e4347 (2009).

  5. 5.

    et al. SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy. Neurology 76, 219–226 (2011).

  6. 6.

    et al. Osteopontin and skeletal muscle myoblasts: association with muscle regeneration and regulation of myoblast function in vitro. Int. J. Biochem. Cell Biol. 40, 2303–2314 (2008).

  7. 7.

    , , & Expression profiling in the muscular dystrophies identification of novel aspects of molecular pathophysiology. J. Cell Biol. 151, 1321–1336 (2000).

  8. 8.

    et al. LTBP4 genotype predicts age of ambulatory loss in Duchenne muscular dystrophy. Ann. Neurol. 73, 481–488 (2013).

  9. 9.

    , , & Genotype-specific interaction of latent TGFbeta binding protein 4 with TGFbeta. PLoS ONE 11, e0150358 (2016).

  10. 10.

    et al. Validation of genetic modifiers for Duchenne muscular dystrophy: a multicentre study assessing SPP1 and LTBP4 variants. J. Neurol. Neurosurg. Psychiatry 86, 1060–1065 (2014).

  11. 11.

    et al. A common nonsense mutation results in alpha-actinin-3 deficiency in the general population. Nat. Genet. 21, 353–354 (1999).

  12. 12.

    et al. Genes for elite power and sprint performance: ACTN3 leads the way. Sports Med. 49, 803–817 (2013).

  13. 13.

    et al. ACTN3 genotype is associated with human elite athletic performance. Am. J. Hum. Genet. 73, 627–631 (2003).

  14. 14.

    et al. ACTN3 genotype is associated with increases in muscle strength in response to resistance training in women. J. Appl. Physiol. 99, 154–163 (2005).

  15. 15.

    et al. Association analysis of the ACTN3 R577X polymorphism and complex quantitative body composition and performance phenotypes in adolescent Greeks. Eur. J. Hum. Genet. 15, 88–93 (2006).

  16. 16.

    , , , & ACTN3 genotype is associated with muscle phenotypes in women across the adult age span. J. Appl. Physiol. 105, 1486–1491 (2008).

  17. 17.

    et al. ACTN3 R577X polymorphism and Israeli top-level athletes. Int. J. Sports Med. 30, 698 (2009).

  18. 18.

    et al. An Actn3 knockout mouse provides mechanistic insights into the association between alpha-actinin-3 deficiency and human athletic performance. Hum. Mol. Genet. 17, 1076–1086 (2008).

  19. 19.

    et al. A gene for speed: contractile properties of isolated whole EDL muscle from an α-actinin-3 knockout mouse. Am. J. Physiol. Cell Physiol. 295, C897–C904 (2008).

  20. 20.

    et al. ACTN3 genotype influences muscle performance through the regulation of calcineurin signaling. J. Clin. Invest. 123, 4255–4263 (2013).

  21. 21.

    et al. Loss of ACTN3 gene function alters mouse muscle metabolism and shows evidence of positive selection in humans. Nat. Genet. 39, 1261–1265 (2007).

  22. 22.

    et al. α-Actinin-3 deficiency results in reduced glycogen phosphorylase activity and altered calcium handling in skeletal muscle. Hum. Mol. Genet. 19, 1335–1346 (2010).

  23. 23.

    et al. Properties of extensor digitorum longus muscle and skinned fibers from adult and aged male and female Actn3 knockout mice. Muscle Nerve 43, 37–48 (2011).

  24. 24.

    , , & Fast muscle fibers are preferentially affected in Duchenne muscular dystrophy. Cell 52, 503–513 (1988).

  25. 25.

    et al. Stimulation of calcineurin signaling attenuates the dystrophic pathology in mdx mice. Hum. Mol. Genet. 13, 379–388 (2004).

  26. 26.

    et al. Activated calcineurin ameliorates contraction-induced injury to skeletal muscles of mdx dystrophic mice. J. Physiol. 575, 645–656 (2006).

  27. 27.

    et al. Reliable surrogate outcome measures in multicenter clinical trials of Duchenne muscular dystrophy. Muscle Nerve 35, 36–42 (2007).

  28. 28.

    , & Abnormalities in structure and function of limb skeletal muscle fibres of dystrophic mdx mice. Proc. Biol. Sci. 248, 163–169 (1992).

  29. 29.

    , & Laminin-111 protein therapy prevents muscle disease in the mdx mouse model for Duchenne muscular dystrophy. Proc. Natl Acad. Sci. USA 106, 7991–7996 (2009).

  30. 30.

    , & Branched fibers in dystrophic mdx muscle are associated with a loss of force following lengthening contractions. Am. J. Physiol. Cell Physiol. 293, C985–C992 (2007).

  31. 31.

    et al. Deficiency of alpha-actinin-3 is associated with increased susceptibility to contraction-induced damage and skeletal muscle remodeling. Hum. Mol. Genet. 20, 2914–2927 (2011).

  32. 32.

    et al. Stimulation of slow skeletal muscle fiber gene expression by calcineurin in vivo. J. Biol. Chem. 275, 4545–4548 (2000).

  33. 33.

    et al. Activation of AMP-activated protein kinase increases mitochondrial enzymes in skeletal muscle. J. Appl. Physiol. 88, 2219–2226 (2000).

  34. 34.

    et al. Metabolic remodeling agents show beneficial effects in the dystrophin-deficient mdx mouse model. Skeletal Muscle 2, 1–11 (2012).

  35. 35.

    et al. Chronic AMPK activation evokes the slow, oxidative myogenic program and triggers beneficial adaptations in mdx mouse skeletal muscle. Hum. Mol. Genet. 20, 3478–3493 (2011).

  36. 36.

    Duchenne muscular dystrophy: clinical trials and emerging tribulations. Curr. Opin. Neurol. 28, 542–546 (2015).

  37. 37.

    , , , & Progress and prospects of gene therapy clinical trials for the muscular dystrophies. Hum. Mol. Genet. 25, R9–R17 (2016).

  38. 38.

    & What can we learn from clinical trials of exon skipping for DMD? Mol. Ther. Nucleic Acids 3, e152 (2014).

  39. 39.

    , & Increased susceptibility of EDL muscles from mdx mice to damage induced by contractions with stretch. J. Muscle Res. Cell M. 14, 446–451 (1993).

  40. 40.

    , , , & Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc. Natl Acad. Sci. USA 90, 3710–3714 (1993).

  41. 41.

    & The role of branched fibres in the pathogenesis of Duchenne muscular dystrophy. Exp. Physiol. 96, 564–571 (2011).

  42. 42.

    Branched fibres in old dystrophic mdx muscle are associated with mechanical weakening of the sarcolemma, abnormal Ca2+ transients and a breakdown of Ca2+ homeostasis during fatigue. Exp. Physiol. 95, 641–656 (2010).

  43. 43.

    et al. Analysis of the ACTN3 heterozygous genotype suggests that alpha-actinin-3 controls sarcomeric composition and muscle function in a dose-dependent fashion. Hum. Mol. Genet. 25, 866–877 (2016).

  44. 44.

    et al. Differential expression of the actin-binding proteins, α-actinin-2 and-3, in different species: implications for the evolution of functional redundancy. Hum. Mol. Genet. 10, 1335–1346 (2001).

  45. 45.

    , & Defective regulation of energy metabolism in mdx-mouse skeletal muscles. Biochem. J. 304, 649–654 (1994).

  46. 46.

    , , & Defects in mitochondrial localization and ATP synthesis in the mdx mouse model of Duchenne muscular dystrophy are not alleviated by PDE5 inhibition. Hum. Mol. Genet. 22, 153–167 (2013).

  47. 47.

    , , & Damage to developing mouse skeletal muscle myotubes in culture: protective effect of heat shock proteins. J. Physiol. 548, 837–846 (2003).

  48. 48.

    et al. Functional improvement of dystrophic muscle by myostatin blockade. Nature 420, 418–421 (2002).

  49. 49.

    et al. Common pathological mechanisms in mouse models for muscular dystrophies. FASEB J. 20, 127–129 (2006).

  50. 50.

    , , & Sarcopenia of aging: underlying cellular mechanisms and protection by calorie restriction. Biofactors 35, 28–35 (2009).

  51. 51.

    , , , & Increased muscle PGC-1α expression protects from sarcopenia and metabolic disease during aging. Proc. Natl Acad. Sci. USA 106, 20405–20410 (2009).

  52. 52.

    et al. Genetic modifiers of ambulation in the Cooperative International Neuromuscular Research Group Duchenne natural history study. Ann. Neurol. 77, 684–696 (2015).

  53. 53.

    et al. Severe muscular dystrophy in mice that lack dystrophin and α7 integrin. J. Cell. Sci. 119, 2185–2195 (2006).

  54. 54.

    , , , & Functional deficits in nNOSmu-deficient skeletal muscle: myopathy in nNOS knockout mice. PLoS ONE 3, e3387 (2008).

  55. 55.

    , , , & Properties of regenerated mouse extensor digitorum longus muscle following notexin injury. Exp. Physiol. 99, 664–674 (2014).

  56. 56.

    , & NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671–675 (2012).

  57. 57.

    , , & Validation of an automated computational method for skeletal muscle fibre morphometry analysis. Neuromusc. Disord. 20, 540–547 (2010).

  58. 58.

    et al. Evidence based selection of commonly used RT-qPCR reference genes for the analysis of mouse skeletal muscle. PLoS ONE 9, e88653 (2014).

Download references


This project was funded in part by grants from the National Health and Medical Research Council of Australia (1002033 and 1062500). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

Author information

Author notes

    • Marshall W. Hogarth
    •  & Peter J. Houweling

    These authors contributed equally to this work


  1. Institute for Neuroscience and Muscle Research, The Children’s Hospital Westmead, New South Wales 2145, Australia

    • Marshall W. Hogarth
    • , Peter J. Houweling
    • , Kristen C. Thomas
    •  & Kathryn N. North
  2. Discipline of Paediatrics and Child Health, Faculty of Medicine, University of Sydney, New South Wales 2006, Australia

    • Marshall W. Hogarth
    •  & Kathryn N. North
  3. School of Medical Sciences, University of New South Wales, New South Wales 2052, Australia

    • Peter J. Houweling
    •  & Stewart I. Head
  4. Murdoch Childrens Research Institute, Melbourne, Victoria 3052, Australia

    • Peter J. Houweling
    •  & Kathryn N. North
  5. Department of Paediatrics, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria 3010, Australia

    • Peter J. Houweling
    •  & Kathryn N. North
  6. Research Centre for Genetic Medicine, Children’s National Medical Centre, Washington DC 20010, USA

    • Heather Gordish-Dressman
    • , Luca Bello
    •  & Eric P. Hoffman
  7. Department of Neurosciences, University of Padova, Padova 35122, Italy

    • Luca Bello
    •  & Elena Pegoraro
  8. Sundaram Medical Foundation and Apollo Children's Hospital, Chennai, India

    • V. Vishwanathan
    •  & S. Chidambaranathan
  9. Holland Bloorview Kids Rehab Hospital, Toronto, Ontario, Canada

    • W. Douglas Biggar
    •  & Laura C. McAdam
  10. Alberta Children's Hospital, Calgary, Alberta, Canada

    • Jean K. Mah
  11. Queen Silvia Children's Hospital, Göteborg, Sweden

    • Mar Tulinius
  12. Children's National Medical Center, Washington DC, USA

    • Avital Cnaan
    • , Lauren P. Morgenroth
    • , Robert Leshner
    • , Carolina Tesi-Rocha
    • , Mathula Thangarajh
    •  & Tina Duong
  13. Royal Children's Hospital, Melbourne, , Victoria, Australia

    • Andrew Kornberg
    •  & Monique Ryan
  14. Hadassah Hebrew University Hospital, Jerusalem, Israel

    • Yoram Nevo
  15. Instituto de Neurosciencias Fundacion Favaloro, Buenos Aires, Argentina

    • Alberto Dubrovsky
  16. University of Pittsburgh and Department of Veterans Affairs, Pittsburgh, Pennsylvania, USA

    • Paula R. Clemens
    •  & Hoda Abdel-Hamid
  17. Washington University in St Louis, St Louis, Missouri, USA

    • Anne M. Connolly
    •  & Alan Pestronk
  18. Children's Hospital of Virginia, Richmond, Virginia, USA

    • Jean Teasley
  19. University of Tennessee, Memphis, Tennessee, USA

    • Tulio E. Bertorini
  20. Children's Hospital at Westmead, Sydney, New South Wales, Australia

    • Richard Webster
  21. University of Alberta, Edmonton, Alberta, Canada

    • Hanna Kolski
  22. Mayo Clinic, Rochester, Minnesota, USA

    • Nancy Kuntz
    • , Sherilyn Driscoll
    •  & John B. Bodensteiner
  23. University of Puerto Rico, San Juan, Puerto, Rico

    • Jose Carlo
  24. University of Pavia and Niguarda Ca' Granda Hospital, Milan, Italy

    • Ksenija Gorni
  25. Texas Children's Hospital, Houston, Texas, USA

    • Timothy Lotze
  26. University of Minnesota, Minneapolis, Minnesota, USA

    • John W. Day
    •  & Peter Karachunski
  27. University of California, Davis, Sacramento, California, USA

    • Erik K. Henricson
    • , Richard T. Abresch
    •  & Craig M. McDonald


  1. Cooperative International Neuromuscular Research Group (CINRG)


  1. Search for Marshall W. Hogarth in:

  2. Search for Peter J. Houweling in:

  3. Search for Kristen C. Thomas in:

  4. Search for Heather Gordish-Dressman in:

  5. Search for Luca Bello in:

  6. Search for Elena Pegoraro in:

  7. Search for Eric P. Hoffman in:

  8. Search for Stewart I. Head in:

  9. Search for Kathryn N. North in:


M.W.H., P.J.H., K.C.T., performed all mouse experiments, H.G.-D. and E.P.H. performed CINRG natural history cohort analysis, L.B. performed Loss of ambulation analysis for all human cohorts, E.P. provided the Padova cohort, S.I.H. performed mouse physiology analyses and K.N.N. conceived the study. M.W.H., P.J.H. and K.N.N. prepared the manuscript, M.W.H. and P.J.H. contributed equally to this work.

Competing interests

E.P.H. has served on advisory committees for AVI BioPharma, Inc., as a consultant with the Gerson Lehman Group, Medacorp, and Lazard Capital, and is cofounder, board member, and shareholder of ReveraGen Biopharma. The remaining authors declare no competing financial interests.

Corresponding author

Correspondence to Kathryn N. North.

Supplementary information

PDF files

  1. 1.

    Supplementary Information

    Supplementary 1-6 and Supplementary Table 1


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit